Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
【저자키워드】 viral infection, Infectious diseases, 【초록키워드】 SARS-CoV-2, Vaccine, coronavirus, vaccine doses, antibody, neutralization, SARS-CoV-2 variant, severe acute respiratory syndrome Coronavirus, variants, Viral, COVID-19 infection, SARS-CoV-2 variants, vaccine response, symptomatic, Effectiveness, Viral variants, antibody levels, respiratory, Neutralizing antibody response, binding, booster vaccination, Decline, vaccine responses, Messenger RNA, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, indication, indications, neutralizing antibody responses, effective, identify, reduced, highlighting, the timing, 【제목키워드】 SARS-CoV-2, vaccination, neutralization, Antibody Response, variant,